VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the firs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback